Compare Adobe Systems Inc (ADBE) vs Alnylam Pharmaceuticals, Inc. (ALNY) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adobe Systems Inc vs Alnylam Pharmaceuticals, Inc. — how do they compare? Adobe Systems Inc trades at $219.89 (market cap $88.06B), while Alnylam Pharmaceuticals, Inc. trades at $320.72 (market cap $42.94B). The key difference: Adobe Systems Inc is far larger — about 2.1× Alnylam Pharmaceuticals, Inc.'s market cap. Which is the better fit depends on your goals.
| ADBE | ALNY | |
|---|---|---|
Market Cap | $88.06B | $42.94B |
Volume | 5,187,646 | — |
Sector | Technology | Health |
52-Week High | $382.24 | $491.22 |
52-Week Low | $193.41 | $278.09 |
Enterprise Value | $89.50B | $41.20B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Adobe (ADBE) trades at $219.75, up 0.77% with strong fundamentals including 29.99% net margin and consistent earnings beats. The stock shows bullish technical signals despite recent volatility, with support at $218 and resistance at $228. Revenue growth accelerated to $23.77B in 2025, while institutional activity remains mixed amid AI competition concerns.
ADBE presents a compelling value opportunity with a 12.67 P/E ratio and 49% analyst buy ratings, though AI disruption fears and CEO transition create near-term uncertainty. The consensus price target of $246.75 implies 12% upside potential, balanced against sector-wide software pressures.
Alnylam Pharmaceuticals (ALNY) trades at $321.59, up 2.82% today, with a bullish technical signal supported by moving averages. The company reported strong revenue growth, reaching $3.71 billion in 2025, and turned profitable with net income of $313.75 million. Recent news highlights its AI partnerships and expanding drug pipeline as key growth drivers.
The outlook is positive, with a consensus price target of $435.40 implying 35% upside, driven by robust revenue growth and pipeline advancements. Risks include dependence on key drug Amvuttra and high valuation multiples. Analyst sentiment is strongly bullish, with 75% recommending Buy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adobe Systems Inc
Adobe Inc. develops, markets, and supports computer software products and technologies. The Company's products allow users to express and use information across all print and electronic media. Adobe offers a line of application software products, type products, and content for creating, distributing, and managing information.
Read more on ADBE →About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →
